• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
  

PubMed=9436977; DOI=10.1101/gad.12.2.163; PMCID=PMC316442
Yeager T.R., DeVries S., Jarrard D.F., Kao C., Nakada S.Y., Moon T.D., Bruskewitz R., Stadler W.M., Meisner L.F., Gilchrist K.W., Newton M.A., Waldman F.M., Reznikoff C.A.
Overcoming cellular senescence in human cancer pathogenesis.
Genes Dev. 12:163-174(1998)

PubMed=10919661
Sarkar S., Julicher K.P., Burger M.S., Della Valle V., Larsen C.-J., Yeager T.R., Grossman T.B., Nickells R.W., Protzel C., Jarrard D.F., Reznikoff C.A.
Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Cancer Res. 60:3862-3871(2000)

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)